2.56 USD
▼+0.09-3.76%
2026-08-03
市值
$20.46M
市盈率
—
EPS
-6.35
股息率
—
52 周区间
2.20 – 6.52
成交量
38.79K
Beta
0.55
目标价
11.50
52W 低 2.2052W 高 6.52
价格走势
公司简介
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company’s lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom’s macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin’s lymphoma cohort; Phase 1 cli...